221
Participants
Start Date
November 30, 2010
Primary Completion Date
June 30, 2012
Study Completion Date
June 30, 2012
CDP6038
60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
CDP6038
120 mg sc at Weeks 0, 2, 4 6, 8, and 10
CDP6038
240 mg sc at Weeks 0, 2, 4 6, 8, and 10
Tocilizumab (Actemra or RoActemra)
8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
CDP6038
60 mg sc at Weeks 0, 4 and 8
CDP6038
240 mg sc at Weeks 0, 4 and 8
CDP6038
120 mg sc at Weeks 0, 4 and 8
Placebo sc
0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
Placebo sc
0.9% Sodium chloride for injection at Weeks 2, 6 and 10
Placebo iv
0.9% Sodium chloride for injection at Weeks 0, 4 and 8
166, Mesa
154, Paradise Valley
118, Scottsdale
103, Hot Springs
125, Jonesboro
127, Covina
148, La Jolla
184, Long Beach
177, Los Angeles
104, Palo Alto
149, Sacramento
158, San Diego
129, Santa Maria
164, Upland
107, Wildomar
141, Hamden
137, Norwalk
101, Trumbull
111, Lewes
176, Aventura
186, Daytona Beach
151, DeBary
114, Jupiter
183, Pinellas Park
178, Sarasota
140, South Miami
157, Tampa
130, Gainesville
162, Newnan
153, Savannah
113, Stockbridge
116, Idaho Falls
160, Moline
156, Rock Island
168, Springfield
133, Cedar Rapids
172, Kansas City
185, Saint Clair Shores
112, St Louis
134, St Louis
102, Lincoln
171, Freehold
163, New Brunswick
152, Toms River
174, Brooklyn
115, Rochester
109, Belmont
170, Charlotte
150, Cincinnati
108, Columbus
100, Dayton
110, Oklahoma City
165, Duncansville
117, Wexford
105, Nashville
106, Nashville
120, Amarillo
135, Austin
128, Dallas
126, Houston
132, Houston
138, Houston
181, Houston
145, Mesquite
143, Nassau Bay
122, San Antonio
144, Tomball
142, Victoria
121, Salt Lake City
139, Chesapeake
119, Seattle
175, Tacoma
136, Beckley
167, Clarksburg
401, Brussels
400, Liège
209, Torquay
201, Wigan
206, Essex
205, London
204, Newcastle upon Tyne
208, Southampton
Lead Sponsor
UCB Pharma
INDUSTRY